News & Updates

Subcutaneous methylnaltrexone is safe to use in children with cancer who have opioid-induced constipation, suggest the results of a study. In addition, this agent stimulates bowel movements in more than a third of paediatric patients.

In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achiev­ing steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with un­complicated mild-to-moderately active inflammatory bowel disease (IBD).

Multiple biosimilar infliximab (IFX) switching among patients with inflammatory bowel disease (IBD) does not seem to give rise to disease flares at 12 months compared to those who continued using IFX originator or those on single IFX biosimilar switch, a study has shown.